GlobeNewsWire
16 Jun 2026, 20:49 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Culper Research alleged that ADMA Biologics engaged in a channel stuffing scheme and used an undisclosed related party distributor to inflate reported growth. — Allegations of financial fraud and artificial revenue inflation are fundamental risks that typically trigger significant sell-offs and loss of investor trust.
-0.80A class action lawsuit has been filed against ADMA Biologics regarding potential securities fraud and unlawful business practices. — Legal action increases the likelihood of financial settlements and adds a layer of regulatory risk to the company's valuation.
-0.50Cantor Fitzgerald downgraded ADMA Biologics due to the company's failure to provide specific feedback addressing the claims in the Culper report. — A downgrade from a known analyst based on poor corporate transparency signals a lack of confidence in management's credibility.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a class action lawsuit alleging securities fraud and channel stuffing, following a short report and a broker downgrade.
The company is the subject of an investigation into investor claims by a law firm.
The company is the subject of an investigation into investor claims by a law firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
